|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 8
Zeitschriftenartikel
Dreyling, M.; Ghielmini, M.; Rule, S.; Salles, G.; Ladetto, M.; Tonino, S. H.; Herfarth, K.; Seymour, J. F. und Jerkeman, M.
(2021):
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines tor diagnosis, treatment and follow-up.
In: Annals of Oncology, Bd. 32, Nr. 3: S. 298-308
Rule, S.; Jurczak, W.; Jerkeman, M.; Rusconi, C.; Trneny, M.; Offner, F.; Caballero, D.; Joao, C.; Witzens-Harig, M.; Hess, G.; Bence-Bruckler, I.; Cho, S-G; Thieblemont, C.; Zhou, W.; Henninger, T.; Goldberg, J.; Vermeulen, J. und Dreyling, M.
(2018):
Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.
In: Leukemia, Bd. 32, Nr. 8: S. 1799-1803
Dreyling, M.; Campo, E.; Hermine, O.; Jerkeman, M.; Gouill, S. le; Rule, S.; Shpilberg, O.; Walewski, J. und Ladetto, M.
(2017):
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
In: Annals of Oncology, Bd. 28: S. 62-71
Younes, A.; Hilden, P.; Coiffier, B.; Hagenbeek, A.; Salles, G.; Wilson, W.; Seymour, J. F.; Kelly, K.; Gribben, J.; Pfreunschuh, M.; Morschhauser, F.; Schoder, H.; Zelenetz, A. D.; Rademaker, J.; Advani, R.; Valente, N.; Fortpied, C.; Witzig, T. E.; Sehn, L. H.; Engert, A.; Fisher, R. I.; Zinzani, P.-L.; Federico, M.; Hutchings, M.; Bollard, C.; Trneny, M.; Elsayed, Y. A.; Tobinai, K.; Abramson, J. S.; Fowler, N.; Goy, A.; Smith, M.; Ansell, S.; Kuruvilla, J.; Dreyling, M.; Thieblemont, C.; Little, R. F.; Aurer, I.; Oers, M. H. J. van; Takeshita, K.; Gopal, A.; Rule, S.; Vos, S. de; Kloos, I.; Kaminski, M. S.; Meignan, M.; Schwartz, L. H.; Leonard, J. P.; Schuster, S. J. und Seshan, V. E.
(2017):
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).
In: Annals of Oncology, Bd. 28, Nr. 7: S. 1436-1447
Lenz, G.; Balasubramanian, S.; Goldberg, J.; Rizo, A.; Schaffer, M.; Phelps, C.; Rule, S. und Dreyling, M.
(2016):
Sequence variants in patients with primary and acquired resistance to Ibrutinib in the phase 3 MCL3001 (RAY) trial.
In: Haematologica, Bd. 101: S. 155
Rule, S.; Dreyling, M.; Hess, G.; Auer, R.; Kahl, B.; Cavazos, N.; Liu, B.; Clow, F.; Goldberg, J.; Beaupre, D.; Vermeulen, J.; Wildgust, M. und Wang, M.
(2016):
Overall survival outcomes in patients with mantle-cell lymphoma (MCL) treated with Ibrutinib in a pooled analysis of 370 patients from 3 international open-label studies.
In: Haematologica, Bd. 101: S. 155
Dreyling, M.; Ghielmini, M.; Rule, S.; Salles, G.; Vitolo, U. und Ladetto, M.
(2016):
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
In: Annals of Oncology, Bd. 27:
v83-v90
Dreyling, Martin; Kluin-Nelemans, H. C.; Bea, Silvia; Hartmann, Elena; Salaverria, Itziar; Hutter, Grit; Perez-Galan, P.; Roue, G.; Pott, Christiane; Le Gouill, Steven; Cortelazzo, Sergio; Rule, S.; Hess, G.; Zaja, F.; Vitolo, U.; Szymczyk, Michal; Walewski, J.; Ribrag, Vincent; Unterhalt, Michael; Hermine, Olivier und Hoster, Eva
(2011):
Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network.
In: Leukemia & Lymphoma, Bd. 52, Nr. 12: S. 2226-2236